ImuneksFarma currently has three healthcare segments; OTC, Pharma (RX), and R&D.
Imuneks’ OTC portfolio is concentrated in the immunology, Ear Nose and Throat, Gastroenterology, Orthopedics and PT areas. These products all have unique benefits to the patients, and are either developed by Imuneks, or by partners with best in class products.
In the RX area, Imuneks has developed three supergeneric products which are already approved in the EU and US markets. These products have improved ease of use, increased efficiency and diminished side effects.
The Imuneks R&D team is working with more than five original pharmaceutiaal treatments and five unique OTC products that are in the pipeline. With two internationally approved patents and a portfolio of new patent applications in different indications, Imuneks Farma is always looking for new and improved ways to treat and cure.
Prof. Dr. Bülent Tarcan Cad.Pak İş Merkezi No:5 Gayrettepe / İstanbul
Contact us at http://www.imuneksfarma.com/
As the international community continues its quest to vaccinate the global population against COVID-19, shortages of already approved vaccines have put many countries on the waiting list. Approved vaccines from…
Ümit Dereli is secretary general of the Turkish Association of Research-Based Pharmaceutical Companies (AIFD), which has 35 multinational member companies that together account for almost 50 percent of the Turkish…
When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in September 2020, it represented a historic moment for Turkey’s pharma industry; the first time a Turkish…
There is perhaps no Turkish company in the healthcare sector that is more ambitious than Acıbadem. Not only has the private hospital group revolutionized healthcare in Turkey with its advanced…
Dr Ferhat Farsi, CEO and founding partner of CinnaGen İlaç, shares his experience working for the largest biotech in the MENA region, Turkey’s important role within the global group, and…
Şükran Tümay, a senior partner at executive search and assessment firm Stanton Chase in Turkey, highlights the evolving profiles she looks for when hiring country managers for healthcare and the…
Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its neighbours – stands as one of the…
Bucking a global trend for increased focus on outpatient and preventative care, Turkey is doubling down on hospital investment. Throughout many of the healthcare systems in North America and Europe, there…
Armağan Vurdu, general secretary of the Istanbul Minerals and Metals Exporters Association (IMMIB) highlights the strategic importance of the chemical and pharmaceutical sectors in Turkey’s exports. He underscores pharma’s role…
Ozlem Fidanci, CEO of the Middle East and Turkey at Philips, shares the collaborative approach Philips has implemented in Turkey and its successes, provides insights into future collaborations and discusses…
Yelda Ulu Colin, general manager of GE Healthcare in Turkey, offers her insider take on the country’s city hospitals project, highlighting the strengths of the Turkish PPP model and ultimately…
Seizing the cost competitiveness of the Turkish market and the government’s nurturing of local manufacturing, Turkish companies are looking to harness their geographic positioning and export to developed and developing…
See our Cookie Privacy Policy Here
